Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
A Retrospective, Non-interventional, Epidemiologic Study of the Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Sydney, Australia
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
-
-
-
Le Kremlin-Bicêtre, France
-
Paris, France
-
Toulouse, France
-
-
-
-
-
Rotterdam, Netherlands
-
-
-
-
-
Moscow, Russian Federation
-
-
-
-
-
Istanbul, Turkey
-
-
-
-
-
Manchester, United Kingdom
-
Sheffield, United Kingdom
-
-
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Indiana
-
Indianapolis, Indiana, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
Springfield, Missouri, United States
-
-
North Carolina
-
Durham, North Carolina, United States
-
-
Ohio
-
Cincinnati, Ohio, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Documented informed consent unless patient is deceased
- Patients with Juvenile-onset HPP, defined as documented onset of first signs/symptoms at ≥ 6 months to ˂18 years
- Documented diagnosis of HPP as indicated by skeletal manifestations and low alkaline phosphatase or genotyping
Exclusion Criteria:
- Received treatment with asfotase alfa in the ENB-006-09 study and/or currently enrolled in the ENB-008-10 study
- Received other treatment and/or intervention to treat HPP up to 15 years old
- Other clinically significant disease
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Radiographic Global Impression of Change - RGI-C
Time Frame: Between Baseline (earliest available, complete, and readable x-ray set) and all available, readable post-Baseline x-ray sets during the period of patients' aged 5 to 15 years, inclusive.
|
The RGI-C scale is a 7-point ordinal scale that is used to evaluate musculoskeletal characteristics of HPP (eg, metaphyseal fraying, demineralization of distal metaphyses).
The scores range from -3 (severe worsening) to +3 (complete or near-complete healing).
|
Between Baseline (earliest available, complete, and readable x-ray set) and all available, readable post-Baseline x-ray sets during the period of patients' aged 5 to 15 years, inclusive.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Height Z-score From Baseline to Last Assessment
Time Frame: Any available growth data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment while post baselines are time points after Baseline during the defined age period.
|
Height measurements were assigned to Z-scores which were calculated using the Centers for Disease Control and Prevention (CDC) 2000 growth charts and methodology.
The Z-score indicates the number of standard deviations away from the mean.
A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher.
Higher Z-scores indicate a better outcome.
|
Any available growth data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment while post baselines are time points after Baseline during the defined age period.
|
|
Change in Weight Z-score From Baseline to Last Assessment
Time Frame: Any available growth data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment while Post baselines are time points after Baseline during the defined age period.
|
Weight measurements were assigned a Z-score which was calculated using the Centers for Disease Control and Prevention (CDC) 2000 growth charts and methodology.
The Z-score indicates the number of standard deviations away from the mean.
A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher.
Higher Z-scores indicate a better outcome.
|
Any available growth data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment while Post baselines are time points after Baseline during the defined age period.
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rickets Severity Sale - RSS
Time Frame: Any available data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment value during the period.
|
The RSS is a 10-point scale, developed for nutritional rickets, that evaluates the degree of metaphyseal cupping and fraying and the proportion of growth plate affected (10 points = severe cupping/fraying, 0 points = absence of cupping/fraying).
|
Any available data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment value during the period.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ALX-HPP-502
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.